Şuayib Yalçın

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin et al. · The Lancet Oncology · 2018 · 495 citations

Gastrointestinal Oncology, Trifluridine/tipiracil Versus Placebo, Medicine +9

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

Oncology, Hepatology, Medicine +10

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

Peter Reichardt, Yoon‐Koo Kang, Piotr Rutkowski et al. · Cancer · 2015 · 105 citations · Full text

Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival

Fatma Paksoy Türköz, Mustafa Solak, Arife Ulaş et al. · Journal of the Korean Gastric Cancer Association · 2014 · 81 citations · Full text